Patient age should not be a barrier to weight loss surgery

Life expectancy gains seen with reducing HbA1c, SBP, LDL-C, and BMI among individuals with type 2 diabetes

Association seen across multivariable regression, one- and two-sample Mendelian randomization analyses

Each standard deviation increase in BP polygenic risk score linked to 12 percent increased hazard of adverse CV events

Exposure linked to higher fat mass, fat-free mass, adiposity, and fasting glucose; no link seen with BMI, BMI z-score

Additionally, minorities less likely to receive all recommended diabetes care

GLP-1 RA treatment linked to increased risk, especially in trials for weight loss, and with higher doses and longer duration of use

Risks and burdens of postacute outcomes increased in graded manner based on COVID-19 severity

Disparities in prevalence of prediabetes remained stable and were pronounced in subgroup analyses of sex and BMI category

Switching between different generic levothyroxine products not linked to changes in serum thyrotropin levels among U.S. adults